Grifols | GRFS - Ebit


Grifols reported EUR320.55M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD 24.47M 24.7M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.05M 526K Sep/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Immunic USD -22.81M 756K Jun/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
TherapeuticsMD USD -1.77M 699K Sep/2023